KR102615744B1 - mRNA 디스플레이 항체 라이브러리 및 방법(mRNA DISPLAY ANTIBODY LIBRARY AND METHODS) - Google Patents

mRNA 디스플레이 항체 라이브러리 및 방법(mRNA DISPLAY ANTIBODY LIBRARY AND METHODS) Download PDF

Info

Publication number
KR102615744B1
KR102615744B1 KR1020207017165A KR20207017165A KR102615744B1 KR 102615744 B1 KR102615744 B1 KR 102615744B1 KR 1020207017165 A KR1020207017165 A KR 1020207017165A KR 20207017165 A KR20207017165 A KR 20207017165A KR 102615744 B1 KR102615744 B1 KR 102615744B1
Authority
KR
South Korea
Prior art keywords
library
sub
members
cdr1
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207017165A
Other languages
English (en)
Korean (ko)
Other versions
KR20200075028A (ko
Inventor
앤더스 올슨
Original Assignee
난트바이오 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 난트바이오 인코포레이티드 filed Critical 난트바이오 인코포레이티드
Priority to KR1020237043350A priority Critical patent/KR102875544B1/ko
Publication of KR20200075028A publication Critical patent/KR20200075028A/ko
Application granted granted Critical
Publication of KR102615744B1 publication Critical patent/KR102615744B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020207017165A 2017-11-20 2018-11-16 mRNA 디스플레이 항체 라이브러리 및 방법(mRNA DISPLAY ANTIBODY LIBRARY AND METHODS) Active KR102615744B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237043350A KR102875544B1 (ko) 2017-11-20 2018-11-16 mRNA 디스플레이 항체 라이브러리 및 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762588914P 2017-11-20 2017-11-20
US62/588,914 2017-11-20
PCT/US2018/061592 WO2019099882A2 (en) 2017-11-20 2018-11-16 mRNA DISPLAY ANTIBODY LIBRARY AND METHODS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237043350A Division KR102875544B1 (ko) 2017-11-20 2018-11-16 mRNA 디스플레이 항체 라이브러리 및 방법

Publications (2)

Publication Number Publication Date
KR20200075028A KR20200075028A (ko) 2020-06-25
KR102615744B1 true KR102615744B1 (ko) 2023-12-19

Family

ID=66534257

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207017165A Active KR102615744B1 (ko) 2017-11-20 2018-11-16 mRNA 디스플레이 항체 라이브러리 및 방법(mRNA DISPLAY ANTIBODY LIBRARY AND METHODS)
KR1020237043350A Active KR102875544B1 (ko) 2017-11-20 2018-11-16 mRNA 디스플레이 항체 라이브러리 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237043350A Active KR102875544B1 (ko) 2017-11-20 2018-11-16 mRNA 디스플레이 항체 라이브러리 및 방법

Country Status (11)

Country Link
US (3) US11015188B2 (https=)
EP (3) EP4644544A3 (https=)
JP (2) JP7291700B2 (https=)
KR (2) KR102615744B1 (https=)
CN (2) CN111511768B (https=)
AU (1) AU2018367622B2 (https=)
CA (1) CA3082172C (https=)
ES (1) ES2969081T3 (https=)
IL (2) IL316884A (https=)
TW (4) TWI877823B (https=)
WO (1) WO2019099882A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11034951B2 (en) 2017-11-20 2021-06-15 Nantbio, Inc. mRNA display antibody library and methods
US11015188B2 (en) 2017-11-20 2021-05-25 NantBio Inc. MRNA display antibody library and methods
KR102736548B1 (ko) * 2019-01-31 2024-12-02 난트바이오 인코포레이티드 Mrna 디스플레이 항체 라이브러리 및 방법
JP2022548783A (ja) * 2019-09-23 2022-11-21 ツイスト バイオサイエンス コーポレーション 単一ドメイン抗体のバリアント核酸ライブラリー
EP4314075A4 (en) 2021-03-24 2025-04-09 Twist Bioscience Corporation VARIANT NUCLEIC ACID BANKS FOR CD3

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008536473A (ja) * 2004-07-06 2008-09-11 バイオレン，インク． ユニバーサル抗体のライブラリー

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
WO2003099999A2 (en) * 2002-05-20 2003-12-04 Abmaxis, Inc. Generation and selection of protein library in silico
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
GB0500099D0 (en) 2005-01-05 2005-02-09 Cambridge Antibody Tech Methods and means relating to protein variants
KR20080073293A (ko) 2005-10-14 2008-08-08 메디뮨 엘엘씨 항체 라이브러리의 세포 디스플레이
US8716195B2 (en) * 2005-11-14 2014-05-06 Bioren, Inc. Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening
EP2069558B1 (en) * 2006-10-02 2013-05-01 Sea Lane Biotechnologies,llc. Design and construction of diverse synthetic peptide and polypeptide libraries
CN101720368A (zh) * 2007-03-09 2010-06-02 中国抗体制药有限公司 储备多样性最大化的功能性人化抗体文库之构建及应用
AU2008343589A1 (en) * 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
KR100961392B1 (ko) 2008-04-15 2010-06-07 이화여자대학교 산학협력단 항체 파지 표면제시 라이브러리 제조방법, 상기 방법에의해 제조된 항체 파지 표면제시 라이브러리, 상기 항체파지 표면제시 라이브러리 유전자를 포함한 파지미드 벡터
NZ591543A (en) * 2008-09-30 2012-11-30 Abbott Lab Improved antibody libraries
KR20110076906A (ko) * 2008-09-30 2011-07-06 아보트 러보러터리즈 개선된 ｒｎａ 디스플레이 방법
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
ES2551871T3 (es) 2010-01-29 2015-11-24 Morphosys Ag Genotecas combinatorias de anticuerpos de roedor
KR101694832B1 (ko) * 2014-12-31 2017-01-12 앱클론(주) 항체 라이브러리 및 그의 제작방법
EP3246434A1 (en) * 2015-01-13 2017-11-22 Ewha University-Industry Collaboration Foundation Method for preparing novel antibody library and library prepared thereby
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
US11034951B2 (en) 2017-11-20 2021-06-15 Nantbio, Inc. mRNA display antibody library and methods
US11015188B2 (en) 2017-11-20 2021-05-25 NantBio Inc. MRNA display antibody library and methods
KR102736548B1 (ko) 2019-01-31 2024-12-02 난트바이오 인코포레이티드 Mrna 디스플레이 항체 라이브러리 및 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008536473A (ja) * 2004-07-06 2008-09-11 バイオレン，インク． ユニバーサル抗体のライブラリー

Also Published As

Publication number Publication date
US11912756B2 (en) 2024-02-27
TWI693235B (zh) 2020-05-11
JP7628153B2 (ja) 2025-02-07
TWI821545B (zh) 2023-11-11
EP4368716B1 (en) 2026-01-28
EP3713964A4 (en) 2021-08-18
IL274780B2 (en) 2025-04-01
EP4368716A3 (en) 2024-08-21
EP4368716C0 (en) 2026-01-28
AU2018367622B2 (en) 2022-12-22
KR102875544B1 (ko) 2025-10-23
EP3713964B1 (en) 2024-01-17
CN111511768B (zh) 2024-03-26
US20210238587A1 (en) 2021-08-05
US20240190945A1 (en) 2024-06-13
IL274780A (en) 2020-07-30
JP7291700B2 (ja) 2023-06-15
ES2969081T3 (es) 2024-05-16
IL274780B1 (en) 2024-12-01
EP3713964A2 (en) 2020-09-30
EP3713964C0 (en) 2024-01-17
TWI877823B (zh) 2025-03-21
CA3082172C (en) 2022-11-29
EP4644544A3 (en) 2025-12-31
EP4644544A2 (en) 2025-11-05
IL316884A (en) 2025-01-01
KR20230174295A (ko) 2023-12-27
KR20200075028A (ko) 2020-06-25
JP2023109916A (ja) 2023-08-08
WO2019099882A3 (en) 2019-08-01
EP4368716A2 (en) 2024-05-15
CN111511768A (zh) 2020-08-07
WO2019099882A2 (en) 2019-05-23
US20190153432A1 (en) 2019-05-23
CN118206640A (zh) 2024-06-18
JP2021503292A (ja) 2021-02-12
AU2018367622A1 (en) 2020-07-02
TW202045548A (zh) 2020-12-16
TW202402807A (zh) 2024-01-16
CA3082172A1 (en) 2019-05-23
TW202521587A (zh) 2025-06-01
TW201922794A (zh) 2019-06-16
US11015188B2 (en) 2021-05-25

Similar Documents

Publication Publication Date Title
KR102615744B1 (ko) mRNA 디스플레이 항체 라이브러리 및 방법(mRNA DISPLAY ANTIBODY LIBRARY AND METHODS)
JP7839238B2 (ja) ｍＲＮＡディスプレイ抗体ライブラリー及び方法
US20240263355A1 (en) mRNA display antibody library and methods
HK40110900A (zh) Mrna展示抗体文库和方法
HK40027625A (en) An mrna display antibody library and methods
HK40027625B (en) An mrna display antibody library and methods

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200615

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220927

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230428

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231009

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231214

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231214

End annual number: 3

Start annual number: 1

PG1601 Publication of registration